Key Highlights
- Shares climbed 8.72% in today's session to around $26.63, one of the largest moves among dermatology names.
- A Phase 2 trial in infants aged 3 to under 24 months showed rapid skin clearance over four weeks with no serious adverse events.
- A research firm reiterated its Buy rating and raised its price target to $39, citing above-consensus prescription growth.
- Zoryve prescription growth accelerated 8% to 9% quarter over quarter in the third quarter, per the firm's estimate.
New Infant Eczema Data Lifts Sentiment at Dermatology Conferences
Arcutis Biotherapeutics (NASDAQ:ARQT) shares rose sharply in today's session after the company presented new data on Zoryve, its roflumilast cream, at the EADV Congress and the Fall Clinical Dermatology Conference 2026. A Phase 2 trial of Zoryve 0.05% cream in infants aged three to under 24 months showed rapid clearance of skin symptoms over four weeks, with no serious adverse events reported among the 101 participants in the study.
Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company based in California focused on treatments for immune-mediated skin diseases. Zoryve is already approved in cream and foam formulations for conditions including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis.
Prescription Growth and Analyst Support Fuel the Rally
A research firm reiterated its Buy rating on the stock and raised its price target to $39, pointing to Zoryve prescription growth of 8% to 9% quarter over quarter in the third quarter, with sales estimated to come in above consensus. The combination of new clinical data and accelerating prescription trends gave investors two separate reasons to push shares higher during the session.
The stock's single-day move also outpaced a broadly steady healthcare sector, with shares trading well above recent levels and nearing the upper end of their 52-week range.
A Growing Pipeline Behind a Rising Valuation
The company carries a market Capitalization near $3.33 billion. Beyond Zoryve, Arcutis Biotherapeutics is developing JAK1 inhibitors targeting hand eczema, vitiligo, and alopecia areata, along with a checkpoint agonist fusion protein still in earlier-stage development.
Outlook: Pediatric Label Expansion Remains the Next Catalyst
With a regulatory decision on at least one pipeline indication expected in 2027, investors are likely to keep watching for further data from the company's younger-patient studies and continued prescription trends for Zoryve. Today's update adds to a string of catalysts this year for the stock.




_11_17_2026_20_37_58_946960.jpg)

Please wait processing your request...